Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04552847
• Other study ID #: S63678
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: October 7, 2020
• Est. completion date: February 8, 2022

Study information

• Verified date: February 2022
• Source: Universitaire Ziekenhuizen Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the diagnostic performance of Al18F-NOTA-octreotide PET imaging in comparison with the current golden standard, 68Ga-DOTA-somatostatin analog PET, in neuroendocrine tumor patients.

Description:

Part A (main part of the trial): Seventy-five neuroendocrine tumor (NET) patients (M/F, aged 18 years and older) with a routine clinical 68Ga-DOTA-somatostin analog (SSA) PET/CT performed in the last three months or scheduled within three months, will undergo a whole-body Al18F-NOTA-octreotide PET/CT. Part B: At least 10, possibly up to 20 NET patients (M/F, aged 18 years and older) with a routine clinical 68Ga-DOTA-SSA PET/CT performed in the last three months or scheduled within three months, will undergo a whole-body Al18F-NOTA-octreotide PET/MR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: February 8, 2022
• Est. primary completion date: February 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is aged over 18 years.
• Signed Informed Consent.
• Subject is diagnosed with a histologically and/or cytologically confirmed neuroendocrine tumor of all grades of gastroenteropancreatic, pulmonary, neural crest or unknown primary origin.
• Subject should have at least one known tumoral lesion below the level of the submandibular and parotid glands with either a minimum size of 1 cm in at least one dimension on morphological imaging (CT, MRI, ultrasound), or a maximal standardized uptake value (SUVmax) of at least 10 on 68Ga-DOTA-SSA PET, in both cases performed within 4 months prior to study scan. A positive lesion is defined as a volume of increased tracer uptake compared to background, deemed to be caused by the presence of NET cells, and that is unlikely to be attributed to physiological or benign etiology (e.g. inflammation, blood pool retention, excretion, etc.).
• Subject should have a routine clinical 68Ga-DOTA-SSA PET/CT performed within three months prior to the study scan or scheduled within three months after the study scan.
• Female subjects should be (a) post-menopausal, or (b) surgically sterile, or (c) using effective contraceptive with negative pregnancy test. Exclusion Criteria:

Part A and B:

• Subject has a previous or ongoing recurrent or chronic disease, other than a neuroendocrine tumor, at high risk to interfere with the performance or evaluation of the trial according to the judgement of the investigator.
• Subject has had exposure to ionizing radiation (> 1 mSv) in other research studies within the last 12 months.
• Subject has recently (< 30 days or 5 times the plasma half-life of the investigated drug, whichever is longest) participated or is simultaneously participating in another prospective interventional clinical trial.
• Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity (i.e. weight lifting, running, bicycling) beginning 4 days prior to tracer injection up to 1 day after tracer injection.
• Subject is potentially pregnant (urinary hCG test can be performed in case of doubt) or is breast-feeding.
• Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator.
• Subject does not understand the study procedure.
• Subject is mentally or legally incapacitated.

Only for part B:

• Subject has a contra-indication for MR scanning.
• Subject suffers from claustrophobia or cannot tolerate confinement during PET/MR scanning.
• Subject has an impaired renal function: estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m² (the last known value may not date from more than 3 months prior to the study PET/MR; if not available a blood analysis may be performed as part of the trial).
• Subject suffers from diseases for which butylhyoscine bromide (Buscopan®) is contra-indicated: glaucoma, paralytic ileus, severe colitis ulcerosa or myasthenia gravis.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Drug:
• Al18F-NOTA-octreotide
One intravenous injection of 4 MBq/kg

Device:
• PET/CT
Patients in part A of the trial will undergo a whole-body PET/CT scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The CT-scan is a low-dose CT that will be acquired for both PET attenuation correction and anatomical information.
• PET/MR
Patients in part B of the trial will undergo a whole-body PET/MR scan 120 minutes (acceptable range: 105 - 240 minutes) after injection of the tracer. The MR scan is a fully diagnostic MR requiring intravenous contrast (Dotarem®) injection and Buscopan® administration to minimize bowel movement.

Locations

Country	Name	City	State
Belgium	Universitaire Ziekenhuizen Leuven	Leuven

Sponsors (4)

Lead Sponsor	Collaborator
Universitaire Ziekenhuizen Leuven	NETwerk, Belgium, University Hospital, Antwerp, University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. [(18)F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [(68)Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub 2020 Jul 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differential detection ratio (DDR)	The fraction of lesions detected by one tracer is the detection ratio. In case of non-inferiority, the difference in detection ratio on Al18F-NOTA-octerotide PET and the detection ratio on 68Ga-DOTA-SSA PET, i.e. the differential detection ratio (DDR), equals zero. The primary objective will be met if the lower margin of the 95% confidence interval for the DDR is higher than -15%. Readers will be blinded for the radiopharmaceutical that is used. (only for part A of the trial)	2 years
Secondary	Lesion detection rate on the organ level	A sub analysis will be performed, involving a lesion count per organ to determine the sensitivity of Al18F-NOTA-octreotide PET and 68Ga-DOTA-SSA PET on the organ level.	2 years
Secondary	Lesion uptake	Standardized uptake value (SUV) measurements will be performed: SUVmax for lesions and SUVmean for several background areas will be determined. Lesion uptake, in terms of SUVmax and tumor-to-background ratio (TBR), will be compared for both tracers.	2 years
Secondary	Clinical impact on TNM staging or patient management	We will evaluate whether different findings with both tracers have a clinical impact, e.g. leading to different TNM staging or differences in patient management. (only part A of the trial as this will be blinded)	2.5 years
Secondary	Lesion detection rate according to the specific 68Ga-DOTA-SSA used for the routine PET scan	Due to the multicenter nature of this study, two or three different standard PET tracers will be used for the routine clinical care 68Ga-DOTA-SSA PET: 68Ga-DOTATATE (current standard in UZ Leuven), 68Ga-DOTANOC (current standard in UZ Antwerp), and potentially 68Ga-DOTATOC (depending where patients from UZ Ghent are scanned). Therefore, the diagnostic performance of Al18F-NOTA-octreotide PET will also be compared with the two or three 68Ga-DOTA-SSAs tracers separately.	2 years
Secondary	Lesion detection rate according to tumor grade	A sub analysis will be performed, comparing the diagnostic performance and lesion uptake with Al18F-NOTA-octreotide and 68Ga-DOTA-SSA between low-grade and high-grade NETs.	2 years
Secondary	Overall diagnostic image quality according to a five-point Likert-scale	As part of an inter-observer agreement analysis, readers will score overall diagnostic image quality using a five-point Likert-scale: (1) non diagnostic, (2) poor, (3) sufficient, (4) good and (5) excellent.	3 years
Secondary	Lesion conspicuity according to a five-point Likert-scale	As part of an inter-observer agreement analysis, readers will score lesion conspicuity relative to the surrounding background using a five-point Likert-scale: (1) no increased uptake (equal or lower than background uptake), (2) barely perceived (slightly higher than background uptake), (3) moderately detectable (higher than background uptake, but less than twice, or less than 5 standardized uptake value (SUV) units above, the background uptake), (4) definitely detected (at least twice the background uptake and at least 5 SUV units higher than background uptake) and (5) strikingly evident/easily spotted (evident on maximum intensity projection images and typically higher than uptake in all normal organs, including the spleen).	3 years
Secondary	Diagnostic confidence according to a five-point Likert-scale	As part of an inter-observer agreement analysis, for each focus of increased non-physiologic uptake readers will score diagnostic confidence using a five-point Likert-scale: (1) definitely no lesion, (2) probably no lesion, (3) indeterminate, (4) probably a lesion, (5) definitely a lesion.	3 years
Secondary	Whole-body MRI correlate of the lesions detected by the PET scans	For the union of lesions identified on both PET scans, MRI images will be checked for corresponding MRI lesions. If a correlating lesion is detected and deemed to be of malignant nature by an experienced whole-body MRI radiologist, the PET lesions will be considered true positives. (only part B of the trial)	2.5 years
Secondary	Effect of Al18F-NOTA-octreotide injection on blood pressure	The impact of Al18F-NOTA-octreotide administration on blood pressure (in mmHg) will be assessed. This parameter and changes from baseline values will be scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03	2 years
Secondary	Effect of Al18F-NOTA-octreotide injection on heart rate	The impact of Al18F-NOTA-octreotide administration on heart rate (in beats per minute) will be assessed. This parameter and changes from baseline values will be scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03	2 years